<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Cui K</submitter><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>756-770</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12449461</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>133(6)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Hyperactive ribosome biogenesis is a hallmark of tumours. Current ribosome-related studies are concentrated on cancer cells. Ribosomes can regulate both tumour and non-cancer cells within the tumour microenvironment, yet the immunomodulatory effects of cellular ribosome biogenesis blockade remain inadequately understood.&lt;h4>Methods&lt;/h4>We performed ribosome-targeting therapy utilizing CX-5461, an effective and acknowledged selective inhibitor of ribosome biogenesis, in immunocompetent in vivo models and submitted for single-cell RNA sequencing (scRNA-seq). Additional large-scale human scRNA-seq data, in-house clinical samples and assays were used.&lt;h4>Results&lt;/h4>Ribosome inhibition elevated lymphoid cell cytotoxic granule secretion and macrophage pro-inflammation reprogr</pubmed_abstract><journal>British journal of cancer</journal><pubmed_title>Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy.</pubmed_title><pmcid>PMC12449461</pmcid><funding_grant_id>82303115</funding_grant_id><funding_grant_id>82472671</funding_grant_id><funding_grant_id>T2250710184</funding_grant_id><pubmed_authors>Wan Q</pubmed_authors><pubmed_authors>Cui K</pubmed_authors><pubmed_authors>Zhu Y</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Wang C</pubmed_authors><pubmed_authors>Li Q</pubmed_authors><pubmed_authors>Gong Z</pubmed_authors><pubmed_authors>Zhang Q</pubmed_authors><pubmed_authors>Tang H</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Liu B</pubmed_authors><pubmed_authors>Gong L</pubmed_authors><pubmed_authors>Shen R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy.</name><description>&lt;h4>Background&lt;/h4>Hyperactive ribosome biogenesis is a hallmark of tumours. Current ribosome-related studies are concentrated on cancer cells. Ribosomes can regulate both tumour and non-cancer cells within the tumour microenvironment, yet the immunomodulatory effects of cellular ribosome biogenesis blockade remain inadequately understood.&lt;h4>Methods&lt;/h4>We performed ribosome-targeting therapy utilizing CX-5461, an effective and acknowledged selective inhibitor of ribosome biogenesis, in immunocompetent in vivo models and submitted for single-cell RNA sequencing (scRNA-seq). Additional large-scale human scRNA-seq data, in-house clinical samples and assays were used.&lt;h4>Results&lt;/h4>Ribosome inhibition elevated lymphoid cell cytotoxic granule secretion and macrophage pro-inflammation reprogr</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-07-15T05:55:38.994Z</modification><creation>2026-06-30T03:16:26.749Z</creation></dates><accession>S-EPMC12449461</accession><cross_references><pubmed>40646287</pubmed><doi>10.1038/s41416-025-03109-y</doi></cross_references></HashMap>